At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials ...

For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous ...

DengiAll emerges as a promising single-dose solution offering balanced protection against all four dengue types.

After years of rising infections and fatalities, Karnataka’s aggressive enforcement, community compliance, and hospital ...

Dengue comes with fever, body pain, and a whole lot of confusion, especially when it comes to treatment. The moment someone ...

After nearly two decades of research, India’s first dengue vaccine, DengiAll, is ready to make its mark. Designed to fight ...

The shares of Panacea Biotec touched its 52-week high of ₹581 on May 15, 2025, and a 52-week low of ₹282.15 on February 28, ...

Two suspected Nipah virus cases in West Bengal’s Barasat have put health authorities on high alert. Amid the disease outbreak ...

Glaucoma often described as the “silent thief of sight” affects millions in India with most cases remaining undiagnosed.

Health authorities in Hong Kong have raised concerns over dengue and chikungunya risks as two imported dengue cases are ...

The company said a total of 10,335 participants have been enrolled in the late stage trial. Each participant will be ...

In a significant effort to speed up diagnosis of serious infections - a move that experts say could also help reduce ...